Claims

1. A compound having a structure as shown below:



;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 having a structure as shown below:



;

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutically acceptable salt as shown below:



$H_2SO_4 \cdot H_2O$.

4. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 3, together with at least one pharmaceutically acceptable excipient.

5. A combination comprising:

a first therapeutic agent which is the pharmaceutically acceptable salt of claim 3;

and a second therapeutic agent independently selected from:

isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin, rifapentine, clofazimine, bedaquiline (TMC207), nitroimidazo-oxazine PA-824, delamanid (OPC-67683), an oxazolidinone, EMB analogue SQ109, a benzothiazinone, a dinitrobenzamide and an antiviral agent including an antiretroviral agent.

6. The combination according to claim 5, wherein the oxazolidinone is linezolid, tedizolid, radezolid, sutezolid (PNU-100480), or posizolid (AZD-5847).

7. The combination according to claim 5, wherein the second therapeutic agent is selected from a therapeutic agent approved or recommended for the treatment of tuberculosis.

8. The combination according to claim 5, wherein the antiviral agents is an antiretroviral agent independently selected from zidovudine, didanosine, lamivudine, zalcitabine, abacavir, stavudine, adefovir, adefovir dipivoxil, fozivudine, todoxil, emtricitabine, alovudine, amdoxovir, elvucitabine, nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, capravirine, lersivirine, GSK2248761, TMC-278, TMC-125, etravirine, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, brecanavir, darunavir, atazanavir, tipranavir, palinavir, lasinavir, enfuvirtide, T-20, T-1249, PRO-542, PRO-140, TNX-355, BMS-806, BMS-663068 and BMS-626529, 5-Helix, raltegravir, elvitegravir, GSK1349572, GSK1265744, vicriviroc (Sch-C), Sch-D, TAK779, maraviroc, TAK449, didanosine, tenofovir, lopinavir, or darunavir.

9. Use of the pharmaceutically acceptable salt of claim 3 in the manufacture of a medicament for killing mycobacteria and/or inhibiting the replication of mycobacteria that cause disease in an animal, wherein the animal infected with mycobacteria is to be contacted with a therapeutically effective amount of the pharmaceutically acceptable salt of claim 3.

10. The use according to claim 9, wherein the mycobacteria is *Mycobacterium tuberculosis*, *Mycobacterium abscessus*, or *Mycobacterium avium*.

11. The use according to claim 10, wherein the disease is tuberculosis.

12. The use according to claim 10, wherein the disease is selected from Johne's disease, Crohn's disease, pulmonary disease or pulmonary infection, Lady Windermere syndrome, *Mycobacterium avium* complex (MAC) lung disease, disseminated *Mycobacterium avium* complex (DMAC), disseminated *Mycobacterium avium intraceullulare* complex

(DMAIC), hot-tub lung, MAC mastitis, MAC pyomyositis, *Mycobacterium avium* paratuberculosis, or granuloma disease.

13. The use according to claim 10, wherein the animal is a human.

14. Use of: (i) the pharmaceutically acceptable salt of claim 3; (ii) the combination of claim 5; or (iii) the pharmaceutical composition according to claim 4, in the manufacture of a medicament for treating a mammal with a disease resulting from a mycobacterial infection,

wherein the mammal in need of such treatment is to be administered with a therapeutically effective amount of said (i) pharmaceutically acceptable salt of claim 3; (ii) combination of claim 5; or (iii) pharmaceutical composition according to claim 4.

15. The use according to claim 14, wherein the mycobacterial infection is an infection of a mycobacterium selected from *Mycobacterium tuberculosis, Mycobacterium abscessus* or *Mycobacterium avium*.

16. The use according to claim 15, wherein the disease is selected from tuberculosis, Johne's disease, Crohn's disease, pulmonary disease or pulmonary infection, Lady Windermere syndrome, *Mycobacterium avium* complex (MAC) lung disease, disseminated *Mycobacterium avium* complex (DMAC), disseminated *Mycobacterium avium intraceullulare* complex (DMAIC), hot-tub lung, MAC mastitis, MAC pyomyositis, *Mycobacterium avium* paratuberculosis, or granuloma disease.

17. The use according to claim 15, wherein the disease is tuberculosis.

18. Use of the pharmaceutically acceptable salt of claim 3 in the manufacture of a medicament for treating a mycobacterial infection in a mammal, wherein the mammal in need of such treatment is to be administered with an effective amount of the pharmaceutically acceptable salt of claim 3.

19. The use according to claim 18, wherein the mycobacterial infection is a *Mycobacterium tuberculosis infection* and the mammal is a human.

20. A compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 3, a pharmaceutical composition according to claim 4 or a combination according to any one of claims 5 to 8, for use in therapy.